On November 11, 2026, cellular immunotherapy congresses evaluated expanded multicenter data for Breyanzi® (Lisocabtagene maraleucel / liso-cel) by Bristol Myers Squibb across relapsed or refractory large B-cell lymphoma (LBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

Distinguished by its proprietary defined 1:1 ratio of CD4+ and CD8+ CAR-positive T-cells, Breyanzi provides potent antilymphoma efficacy while maintaining an exceptionally low incidence of severe Cytokine Release Syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), permitting outpatient administration in certified academic cancer centers.

Through Critical Kare Pharma, specialized cellular therapy logistics experts coordinate temperature-monitored cryogenic dispatch and regulatory support for accredited international transplant programs.

The TRANSFORM & TRANSCEND Trial Benchmarks

• TRANSFORM Phase 3 (Second-Line LBCL): Liso-cel demonstrated superior event-free survival (median 10.1 months vs 2.3 months) and complete response rate (66% vs 39%) compared to standard salvage chemotherapy followed by autologous stem cell transplantation.
• TRANSCEND FL (Relapsed/Refractory Follicular Lymphoma): Achieved an overall response rate of 97% with an extraordinary 94% complete response rate in heavily pretreated high-risk patients.
• Safety Profile: Grade ≥ 3 CRS occurs in less than 3% of patients, and Grade ≥ 3 neurotoxicity in less than 10%, a substantially safer profile than first-generation autologous CAR-Ts.

Engineering: Defined CD4:CD8 1:1 Composition

Breyanzi is manufactured with independently transduced, purified CD4+ helper and CD8+ cytotoxic T-cell components combined at a precise 1:1 target ratio. This deliberate balance prevents uncontrolled CD8+ clonal spikes that drive lethal inflammatory surges while ensuring robust CD4+ helper cytokine signaling that prevents exhaustion and sustains multi-year memory persistence.

Logistics & Cell Transit

Vapor-phase liquid nitrogen storage (≤ -130°C) is mandatory. Critical Kare Pharma provides specialized cryoshipper tracking, temperature telemetry, and import compliance documentation for global cellular treatment networks.